Prostate Cancer International is a
non-profit for 2012 as rated by Great NonProfits
An article just published on the Medscape web site addresses data on the potential of GenomeDx Bioscence’s new “Decipher” test which “could” (according to one urologic oncologist) help prevent over-treatment of at least some men with prostate cancer. One might ask whether we can — as yet — decipher the value of the Decipher test. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: Decipher, expression, gene, risk, Treatment | 2 Comments »
According to a media release from the Mayo Clinic earlier today, “Alterations to the ‘on-off’ switches of genes occur early in the development of prostate cancer and could be used as biomarkers to detect the disease months or even years earlier than current approaches.” … READ MORE …
Filed under: Diagnosis, Management, Risk | Tagged: aggressiveness, DNA, expression, gene, methylation, test | 2 Comments »
“Manserin” is a novel peptide originally derived from a larger secretory protein called secretogranin II. A newly published paper suggests that expression of manserin in human prostate cancer tissues may correlate with risk for clinically significant and progressive forms of prostate cancer. … READ MORE …
Filed under: Diagnosis, Management, Risk | Tagged: expression, Gleason, immunohistochemistry, manserin, progression, risk | Leave a Comment »
According to a report in the Science section of the Financial Times, “the world’s first nationwide genetic testing programme for cancer patients goes into action in the UK next month, with support from the public, private and charitable sectors.” … READ MORE …
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: Diagnosis, expression, gene, genetics, Management, risk | Leave a Comment »
There are in fact three so-called “isozymes” (slightly different versions) of the human enzyme 5α-steroid reductase. The activity of 5α-reductase-II can be affected by the 5α-reductase inhibitor (5-ARI) finasteride (Proscar); the activity of 5α-reductase-I and -II can be affected by the 5-ARI dutasteride (Avodart), but … READ MORE …
Filed under: Drugs in development, Prevention | Tagged: 5α-reductase, expression, inhibition | 1 Comment »
As usual, some of our friends in the media are over-hyping a recent publication about the possible effects of a protein called FUS/TLS in the progression of prostate cancer. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: expression, FUS, FUS/TLS, progression, protein | Leave a Comment »
A research team at the University of Miami has come up with an innovative new method that (please note the emphasis) might offer a completely new way to eliminate remaining cancer cells in patients with prostate and other types of cancer after first-line therapy. … READ MORE …
Filed under: Drugs in development | Tagged: antigen, cancer cell, expression, immunity, tumor | Leave a Comment »
Today’s news reports cover items on:
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Management, Risk, Treatment, Uncategorized | Tagged: biopsy, CRPC, ERG, expression, gene, IMRT, PTEN, RALP, side effects, toxicity, urinary, voiding | Leave a Comment »
In today’s news reports we discuss:
Filed under: Diagnosis, Drugs in development, Management, Risk, Treatment | Tagged: chemotherapy, expression, gene, ginger, intermediate, ixabepilone, mitoxantrone, nausea, risk | Leave a Comment »
There are just two notable reports in today’s early news:
Filed under: Diagnosis, Management, Risk, Uncategorized | Tagged: age, expression, outcome, PSM2, survival | Leave a Comment »
Search for new and
ongoing trials on the
CTAG PCa web site